Work

A Case for the Use of Receiver Operating Characteristic Analysis of Potential Clinical Efficacy Biomarkers in Advanced Renal Cell Carcinoma

Year: 2015

Type: article

Abstract: AIM: Assess patient-level utility of suggested pretreatment biomarkers of sunitinib in advanced renal cell carcinoma. PATIENTS & METHODS: Kaplan-Meier analysis of data from a randomized, Phase II study (n = 292) suggested baseline predictive value for circulating soluble Ang-2 and MMP-2 and HIF-1α percentage of tumor expression. Using this dataset, the sensitivity, specificity and area under the curve (AUC) were calculated, using receiver operating characteristic (ROC) curves. RESULTS: Based on a ROC (sensitivity vs 1 - specificity) threshold AUC value of >0.8, neither Ang-2 (0.67) nor MMP-2 (0.65), nor HIF-1α percentage of tumor expression (0.65), performed appropriately from a patient-selection standpoint. CONCLUSION: To properly assess potential biomarkers, sensitivity and specificity characteristics should be obtained by ROC analysis.

Source: Future Oncology

DOI: 10.2217/fon.15.290

Authors: Patricia A English, J Andrew Williams, Jean-François Martini, Robert J Motzer, Olga Valota, Richard E Buller

Institutions: Pfizer (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Pfizer, National Cancer Institute